CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Grant or award President and CEO acquired 5 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 275,000 shares at $18.00 ($4,950,000)
- 4 Conversion FIL Ltd acquired 3,273,807 shares (conversion)
- 4 Conversion FMR LLC acquired 3,238,676 shares (conversion)
- 4 Conversion 10% owner acquired 8,606,249 shares (conversion)
- 4 Conversion 10% owner acquired 10,756,249 shares (conversion)
- 4 Conversion Director acquired 25,000 shares (conversion)
- 4 Conversion Director acquired 249,998 shares (conversion)
- 4 Conversion Director acquired 62,500 shares (conversion)
- 4 Conversion Director acquired 10,756,249 shares (conversion)
- 4 Conversion Director acquired 250,000 shares (conversion)
- 4 Conversion CFO and Treasurer acquired 500,000 shares (conversion)
- 4 Conversion President and CEO acquired 12,500 shares (conversion)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 21 of 22 · 436 filings